2022-06-30 | ||
---|---|---|
Operating Expenses | 31.55 | |
Research And Development Expense | 23.18 | |
General And Administrative Expense | 6.85 | |
Operating Income Loss | -25.38 | |
Allocated Share Based Compensation Expense | 1.81 | |
Profit Loss | -25.09 | |
Net Income Loss Available To Common Stockholders Basic | -25.09 |
2022-06-30 | ||
---|---|---|
Assets | 208.50 | |
Liabilities | 46.26 | |
Liabilities And Stockholders Equity | 208.50 | |
Stockholders Equity | 162.24 |
2022-06-30 | ||
---|---|---|
Liabilities Current | 21.72 | |
Accounts Payable Current | 5.11 | |
Accrued Liabilities Current | 16.14 | |
Other Liabilities Current | 0.02 | |
Contract With Customer Liability Current | NA |
2022-06-30 | ||
---|---|---|
Other Liabilities Noncurrent | NA | |
Operating Lease Liability Noncurrent | 24.54 |
2022-06-30 | ||
---|---|---|
Net Cash Provided By Used In Operating Activities | -15.88 | |
Net Cash Provided By Used In Investing Activities | -59.59 | |
Net Cash Provided By Used In Financing Activities | 0.07 |
2022-06-30 | ||
---|---|---|
Net Cash Provided By Used In Operating Activities | -15.88 | |
Profit Loss | -25.09 | |
Increase Decrease In Accounts Payable | 0.30 | |
Share Based Compensation | 1.81 |
2022-06-30 | ||
---|---|---|
Net Cash Provided By Used In Investing Activities | -59.59 | |
Payments To Acquire Property Plant And Equipment | 1.14 |
2022-06-30 | ||
---|---|---|
Net Cash Provided By Used In Financing Activities | 0.07 |
2022-06-30 | ||
---|---|---|
Ultragenyx, Related Party, Collaborative Arrangement Transaction With Party To Collaborative Arrangement | 6.17 | |
Related Party | 6.17 |